Eli Lilly and Company (LLY)
After hours:
| Previous Close | 750.77 |
| Open | 749.42 |
| Bid | 743.65 x 1000 |
| Ask | 746.74 x 1100 |
| Day's Range | 743.77 - 752.20 |
| 52 Week Range | 370.68 - 800.78 |
| Volume | |
| Avg. Volume | 3,050,669 |
| Market Cap | 709.224B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 129.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 5.20 (0.69%) |
| Ex-Dividend Date | Feb 14, 2024 |
| 1y Target Est | N/A |
- Insider Monkey
13 Best Low Volatility Stocks to Buy According to Hedge Funds
In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]
- Investor's Business Daily
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
